CSLLY - NIH halts a convalescent plasma trial in patients with mild COVID-19

The National Institutes of Health has halted a clinical trial evaluating the safety and effectiveness of COVID-19 convalescent plasma in emergency room patients with mild to moderate symptoms of COVID-19.Following a second planned interim analysis of the trial data, an independent data and safety monitoring board has determined that the treatment while being harmless is, however, unlikely to benefit this group of patients.The trial launched in August 2020 has evaluated the effectiveness of the use of convalescent plasma also known as “survivor’s plasma” (blood plasma-derived from those who recovered from COVID-19) in adults seeking emergency care after having mild to moderate symptoms for a week or less.In August 2020, the FDA issued an emergency use authorization for convalescent plasma as a treatment option for COVID-19.Related tickers: Liminal BioSciences ([[LMNL]] -4.2%), Renalytix AI ([[RNLX]] -2.7%), Kamada ([[KMDA]] -2.1%), Grifols, ([[GRFS]] -1.5%), XBiotech ([[XBIT]] -0.7%), Cerus ([[CERS]] -0.5%), ADMA Biologics ([[ADMA]] -0.2%), CSL Limited ([[CSLLY]]

For further details see:

NIH halts a convalescent plasma trial in patients with mild COVID-19